Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 717

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 717
---
,243 | ​ | $          | 48,983 |
| More than one year   | ​ |                |                        — | ​ |            |     — | ​ |                |                       — | ​ |            |      — |
| Total                | ​ | $              |                    5,000 | ​ | $          | 4,975 | ​ | $              |                  49,243 | ​ | $          | 48,983 |

All available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Other income, net includes interest and dividends, accretion/amortization of discounts/premiums, realized gains and losses on sales of securities and credit loss expense due to declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method.

There werenosales of available-for-sale marketable securities during each of the three and nine months ended September 30, 2024 and 2023.

As of September 30, 2024 and December 31, 2023, accrued interest receivables on the Company’s available-for-sale debt securities were$ 99and$ 139, respectively, and were included within other receivables.

4. Accumulated Other Comprehensive Loss

The following table summarizes the changes in accumulated other comprehensive loss, net of tax, from unrealized gains on available-for-sale marketable securities, the Company’s only component of accumulated other comprehensive loss, for the nine months ended September 30, 2024 and 2023, respectively.

| ​                                                             
 ​                                                             
 ​                                                             
 ​                                                             | ​ 
 ​ 
 ​ | ​                   
 Total Accumulated   
 Other Comprehensive 
 Loss                |      ​ |
|:--------------------------------------------------------------|:--|:--------------------|-------:|
| Balance, December 31, 2023                                    | ​ | $                   |   -260 |
| Other comprehensive income before reclassifications           | ​ |                     |    235 |
| Amount reclassified from accumulated other comprehensive loss | ​ |                     |      — |
| Net current period other comprehensive income                 | ​ |                     |    235 |
| Balance, September 30, 2024                                   | ​ | $                   |    -25 |
| ​                                                             | ​ | ​                   |      ​ |
| Balance, December 31, 2022                                    | ​ | $                   | -1